Risk factor
Strong & resilient to price shocks
Profitability factor
Greatly overvalued vs peers
About
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued
Target Price
The average target price of LAURUSLABS.NS is 812 and suggests 22% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendatio
Buy
Sell